MedTrace Logo

Antidepressant Controlled Trial for Negative Symptoms in Schizophrenia

NCT01032083 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 62

Last updated 2024-03-28

Study results available
· View outcomes & findings →

Summary

The aim of this double-blind, placebo-controlled trial is to establish the clinical and cost effectiveness of an SSRI antidepressant, citalopram, in the management of persistent negative symptoms of schizophrenia over a year.

Conditions

Interventions

DRUG

Citalopram

Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.

DRUG

Placebo

Treatment with citalopram will be initiated at 20mg/day for the first 4 weeks (or one placebo capsule), followed by the option to increase the dose to 40mg per day (or two placebo capsules) for the remainder of the study period.

Sponsors & Collaborators

  • University of Manchester

    collaborator OTHER

  • University of Southampton

    collaborator OTHER

  • King's College London

    collaborator OTHER

  • University of Oxford

    collaborator OTHER

  • University College, London

    collaborator OTHER

  • University of Bristol

    collaborator OTHER

  • Imperial College London

    lead OTHER

Principal Investigators

  • Thomas R Barnes, MD · Imperial College London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2014-12-31
Completion
2015-01-31

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01032083 on ClinicalTrials.gov